This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.
T-Mobile (TMUS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Investments in new geographies and customer experience are likely to have aided T-Mobile's (TMUS) third-quarter 2019 financial and operating results.
What Awaits SBA Communications (SBAC) This Earnings Season?
by Zacks Equity Research
Robust site leasing operations in both domestic and international markets are likely to have supported SBA Communications' (SBAC) AFFO in third-quarter 2019.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Nokia (NOK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid progress in its expansion areas of Software and Enterprise and excellent momentum in IP Routing business are likely to have benefited Nokia's (NOK) third-quarter 2019 financial results.
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
by Zacks Equity Research
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
by Zacks Equity Research
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Editas Inks Deal for Gene Editing Neurological Disease Drugs
by Zacks Equity Research
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Novavax Begins Phase III Study on Influenza Vaccine Candidate
by Zacks Equity Research
Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
by Zacks Equity Research
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance
by Zacks Equity Research
The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.
Seattle Genetics Begins Phase III Study on Tucatinib Combo
by Zacks Equity Research
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
bluebird Inks Genome Editing Research Deal With Novo Nordisk
by Zacks Equity Research
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
by Zacks Equity Research
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
Incyte Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Incyte has been struggling lately, but the selling pressure may be coming to an end soon.
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
by Zacks Equity Research
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INCY) Outperforming Other Medical Stocks This Year?
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.
Incyte Treats First Patient in Phase III Vitiligo Study
by Zacks Equity Research
Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
by Zacks Equity Research
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
by Zacks Equity Research
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer
by Zacks Equity Research
Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Why Is Incyte (INCY) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.